Everest Medicines Future Growth
Future criteria checks 2/6
Everest Medicines is forecast to grow earnings and revenue by 83.5% and 37.2% per annum respectively. EPS is expected to decline by 2.1% per annum. Return on equity is forecast to be -3.1% in 3 years.
Key information
83.5%
Earnings growth rate
-2.1%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 37.2% |
| Future return on equity | -3.1% |
| Analyst coverage | Low |
| Last updated | 04 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,011 | -16 | -20 | N/A | 3 |
| 12/31/2025 | 1,322 | -250 | -88 | N/A | 5 |
| 12/31/2024 | 696 | -890 | -1,102 | N/A | 5 |
| 6/30/2024 | 419 | -1,053 | N/A | N/A | N/A |
| 3/31/2024 | 272 | -949 | N/A | N/A | N/A |
| 12/31/2023 | 126 | -844 | 545 | -769 | N/A |
| 9/30/2023 | 73 | -424 | 610 | -925 | N/A |
| 6/30/2023 | 21 | -3 | 675 | -1,082 | N/A |
| 3/31/2023 | 17 | -125 | -174 | -1,119 | N/A |
| 12/31/2022 | 13 | -247 | -1,024 | -1,156 | N/A |
| 9/30/2022 | 7 | -770 | -1,479 | -1,006 | N/A |
| 6/30/2022 | 1 | -1,294 | -1,934 | -857 | N/A |
| 3/31/2022 | 1 | -1,151 | -1,820 | -793 | N/A |
| 12/31/2021 | 0 | -1,009 | -1,706 | -730 | N/A |
| 9/30/2021 | 0 | -3,213 | -1,238 | -685 | N/A |
| 6/30/2021 | N/A | -5,418 | -770 | -640 | N/A |
| 3/31/2021 | N/A | -6,154 | -1,092 | -582 | N/A |
| 12/31/2020 | N/A | -5,658 | -992 | -472 | N/A |
| 3/31/2020 | N/A | -10 | -271 | -126 | N/A |
| 12/31/2019 | N/A | -215 | -182 | -89 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6HN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6HN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6HN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6HN's revenue (37.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 6HN's revenue (37.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6HN is forecast to be unprofitable in 3 years.